These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32963049)

  • 21. The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan.
    Li TH; Liao HT; Huang YF; Shen YC; Chiu YC; Chen WS; Chen MH; Tsai CY; Chang DM
    J Formos Med Assoc; 2018 May; 117(5):404-412. PubMed ID: 28552625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
    Coates LC; FitzGerald O; Helliwell PS; Paul C
    Semin Arthritis Rheum; 2016 Dec; 46(3):291-304. PubMed ID: 27388027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comment on: Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.
    Lynch M; Kirby B
    Rheumatology (Oxford); 2010 Jan; 49(1):196-7; author reply 197-8. PubMed ID: 19858119
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
    Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
    Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the real-world benefits and risks of anti-tumor necrosis factor therapies.
    Low A; Hyrich K
    J Rheumatol; 2013 Jan; 40(1):4-6. PubMed ID: 23280161
    [No Abstract]   [Full Text] [Related]  

  • 26. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
    Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
    Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
    Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of rheumatoid and psoriatic arthritis--review of leflunomide].
    Babić-Naglić D; Anić B; Novak S; Grazio S; Martinavić Kaliterna D
    Reumatizam; 2010; 57(2):161-2. PubMed ID: 21875023
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
    Palazzi C; D'Angelo S; Leccese P; Padula A; Olivieri I
    Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
    Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
    Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
    Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
    Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional therapy of psoriatic arthritis: evidence-based review.
    McHugh NJ; Soriano ER
    Reumatismo; 2007; 59 Suppl 1():81-4. PubMed ID: 17828352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologics in Inflammatory and Immunomediated Arthritis.
    Luchetti MM; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
    Agca R; Heslinga SC; Rollefstad S; Heslinga M; McInnes IB; Peters MJ; Kvien TK; Dougados M; Radner H; Atzeni F; Primdahl J; Södergren A; Wallberg Jonsson S; van Rompay J; Zabalan C; Pedersen TR; Jacobsson L; de Vlam K; Gonzalez-Gay MA; Semb AG; Kitas GD; Smulders YM; Szekanecz Z; Sattar N; Symmons DP; Nurmohamed MT
    Ann Rheum Dis; 2017 Jan; 76(1):17-28. PubMed ID: 27697765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis.
    Dalkilic E; Sahbazlar M; Gullulu M; Yavuz M; Dilek K; Ersoy A; Ozkaya G; Yurtkuran M
    Mod Rheumatol; 2013 May; 23(3):525-8. PubMed ID: 22752502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute generalized skin eruption due to adalimumab: report of two cases.
    Dalmau J; Roé E; Corella F; García-Navarro X; Peramiquel L; Alomar A
    J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1105-6. PubMed ID: 17714134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.